Clinical Trial Update: Prevention of the Graft-Versus-Host-Disease in Patients After Stem Cell Transplantation With Tacrolimus and Everolimus [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial evaluating tacrolimus and everolimus to prevent graft-versus-host disease after stem cell transplantation was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Everolimus (everolimus)
• Tacrolimus (Tacrolimus)

Snippet

Sponsor: Technische Universität Dresden | Conditions: Graft vs Host Disease | Phase 2, Phase 3 | Status: TERMINATED